Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Maio, Michele; Schöffski, Patrick; Carlino, Matteo S.; Lebbé, Céleste; McArthur, Grant; Ascierto, Paolo A.; Daniels, Gregory A.; Long, Georgina V.; Bastholt, Lars; Rizzo, Jasmine I.; Balogh, Agnes; Moshyk, Andriy; Guidoboni, Massimo; Haanen, John; Hill, Andrew; Hodi, F. Stephen; Hogg, David; Smylie, Michael; Ferrucci, Pier F.; Dummer, Reinhard; Wagstaff, John; Schadendorf, Dirk; Cowey, C. Lance; Lao, Christopher D.; Rutkowski, Piotr; Grob, Jean-Jacques; Gonzalez, Rene; Chiarion-Sileni, Vanna; Larkin, James; Márquez-Rodas, Ivan; Wolchok, Jedd D.

doi:10.1056/nejmoa1910836

Journal article 685 views 1176 downloads

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Michele Maio, Patrick Schöffski, Matteo S. Carlino, Céleste Lebbé, Grant McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Lars Bastholt, Jasmine I. Rizzo, Agnes Balogh, Andriy Moshyk, Massimo Guidoboni, John Haanen, Andrew Hill, F. Stephen Hodi, David Hogg, Michael Smylie, Pier F. Ferrucci, Reinhard Dummer, John Wagstaff, Dirk Schadendorf, C. Lance Cowey, Christopher D. Lao, Piotr Rutkowski, Jean-Jacques Grob, Rene Gonzalez, Vanna Chiarion-Sileni, James Larkin, Ivan Márquez-Rodas, Jedd D. Wolchok

New England Journal of Medicine, Volume: 381, Issue: 16, Pages: 1535 - 1546

Swansea University Author: John Wagstaff

PDF | Version of Record

Copyright © (2019) Massachusetts Medical Society. Reprinted with permission
Download (345.88KB)

Check full text

DOI (Published version): 10.1056/nejmoa1910836

Abstract

945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipili...

Full description

Published in:	New England Journal of Medicine
ISSN:	0028-4793 1533-4406
Published:	Massachusetts Medical Society 2019
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa52612
Tags:	Add Tag No Tags, Be the first to tag this record!

first_indexed	2019-10-30T19:12:33Z
last_indexed	2023-02-23T04:04:39Z
id	cronfa52612
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2023-02-22T15:49:44.7578368</datestamp><bib-version>v2</bib-version><id>52612</id><entry>2019-10-30</entry><title>Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2019-10-30</date><deptcode>SGMED</deptcode><abstract>945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipilimumab/nivo, 45% of nivo and 19% of Ipilimumab patients. Complete responses were seen in 22% (Ipilimumab/nivo), 19% (nivo) and 6% (Ipi) patients. Overall survival (OS) at five years was 52% (Ipilimumab/nivo), 44% (nivo) and 26% (Ipi). In patients with and without bras mutations the OS at five years was 60 & 48% (Ipilimumab/nivo), 46 & 43% (nivo) and 30 & 25% (Ipi) respectively. OS curves were flat beyond three years indicating that these treatments lead to sustained long term survival of these patients.</abstract><type>Journal Article</type><journal>New England Journal of Medicine</journal><volume>381</volume><journalNumber>16</journalNumber><paginationStart>1535</paginationStart><paginationEnd>1546</paginationEnd><publisher>Massachusetts Medical Society</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0028-4793</issnPrint><issnElectronic>1533-4406</issnElectronic><keywords>Melanoma, ipilimumab, nivolumab, overall survival</keywords><publishedDay>17</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2019</publishedYear><publishedDate>2019-10-17</publishedDate><doi>10.1056/nejmoa1910836</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2023-02-22T15:49:44.7578368</lastEdited><Created>2019-10-30T11:38:16.7725850</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Michele</firstname><surname>Maio</surname><order>1</order></author><author><firstname>Patrick</firstname><surname>Schöffski</surname><order>2</order></author><author><firstname>Matteo S.</firstname><surname>Carlino</surname><order>3</order></author><author><firstname>Céleste</firstname><surname>Lebbé</surname><order>4</order></author><author><firstname>Grant</firstname><surname>McArthur</surname><order>5</order></author><author><firstname>Paolo A.</firstname><surname>Ascierto</surname><order>6</order></author><author><firstname>Gregory A.</firstname><surname>Daniels</surname><order>7</order></author><author><firstname>Georgina V.</firstname><surname>Long</surname><order>8</order></author><author><firstname>Lars</firstname><surname>Bastholt</surname><order>9</order></author><author><firstname>Jasmine I.</firstname><surname>Rizzo</surname><order>10</order></author><author><firstname>Agnes</firstname><surname>Balogh</surname><order>11</order></author><author><firstname>Andriy</firstname><surname>Moshyk</surname><order>12</order></author><author><firstname>Massimo</firstname><surname>Guidoboni</surname><order>13</order></author><author><firstname>John</firstname><surname>Haanen</surname><order>14</order></author><author><firstname>Andrew</firstname><surname>Hill</surname><order>15</order></author><author><firstname>F. Stephen</firstname><surname>Hodi</surname><order>16</order></author><author><firstname>David</firstname><surname>Hogg</surname><order>17</order></author><author><firstname>Michael</firstname><surname>Smylie</surname><order>18</order></author><author><firstname>Pier F.</firstname><surname>Ferrucci</surname><order>19</order></author><author><firstname>Reinhard</firstname><surname>Dummer</surname><order>20</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>21</order></author><author><firstname>Dirk</firstname><surname>Schadendorf</surname><order>22</order></author><author><firstname>C. Lance</firstname><surname>Cowey</surname><order>23</order></author><author><firstname>Christopher D.</firstname><surname>Lao</surname><order>24</order></author><author><firstname>Piotr</firstname><surname>Rutkowski</surname><order>25</order></author><author><firstname>Jean-Jacques</firstname><surname>Grob</surname><order>26</order></author><author><firstname>Rene</firstname><surname>Gonzalez</surname><order>27</order></author><author><firstname>Vanna</firstname><surname>Chiarion-Sileni</surname><order>28</order></author><author><firstname>James</firstname><surname>Larkin</surname><order>29</order></author><author><firstname>Ivan</firstname><surname>Márquez-Rodas</surname><order>30</order></author><author><firstname>Jedd D.</firstname><surname>Wolchok</surname><order>31</order></author></authors><documents><document><filename>52612__16498__4918d35a3c684b7481298e44ab4be851.pdf</filename><originalFilename>52612.pdf</originalFilename><uploaded>2020-01-31T15:06:57.7084700</uploaded><type>Output</type><contentLength>354176</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><embargoDate>2020-04-17T00:00:00.0000000</embargoDate><documentNotes>Copyright © (2019) Massachusetts Medical Society. Reprinted with permission</documentNotes><copyrightCorrect>true</copyrightCorrect></document></documents><OutputDurs/></rfc1807>
spelling	2023-02-22T15:49:44.7578368 v2 52612 2019-10-30 Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2019-10-30 SGMED 945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipilimumab/nivo, 45% of nivo and 19% of Ipilimumab patients. Complete responses were seen in 22% (Ipilimumab/nivo), 19% (nivo) and 6% (Ipi) patients. Overall survival (OS) at five years was 52% (Ipilimumab/nivo), 44% (nivo) and 26% (Ipi). In patients with and without bras mutations the OS at five years was 60 & 48% (Ipilimumab/nivo), 46 & 43% (nivo) and 30 & 25% (Ipi) respectively. OS curves were flat beyond three years indicating that these treatments lead to sustained long term survival of these patients. Journal Article New England Journal of Medicine 381 16 1535 1546 Massachusetts Medical Society 0028-4793 1533-4406 Melanoma, ipilimumab, nivolumab, overall survival 17 10 2019 2019-10-17 10.1056/nejmoa1910836 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2023-02-22T15:49:44.7578368 2019-10-30T11:38:16.7725850 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Michele Maio 1 Patrick Schöffski 2 Matteo S. Carlino 3 Céleste Lebbé 4 Grant McArthur 5 Paolo A. Ascierto 6 Gregory A. Daniels 7 Georgina V. Long 8 Lars Bastholt 9 Jasmine I. Rizzo 10 Agnes Balogh 11 Andriy Moshyk 12 Massimo Guidoboni 13 John Haanen 14 Andrew Hill 15 F. Stephen Hodi 16 David Hogg 17 Michael Smylie 18 Pier F. Ferrucci 19 Reinhard Dummer 20 John Wagstaff 21 Dirk Schadendorf 22 C. Lance Cowey 23 Christopher D. Lao 24 Piotr Rutkowski 25 Jean-Jacques Grob 26 Rene Gonzalez 27 Vanna Chiarion-Sileni 28 James Larkin 29 Ivan Márquez-Rodas 30 Jedd D. Wolchok 31 52612__16498__4918d35a3c684b7481298e44ab4be851.pdf 52612.pdf 2020-01-31T15:06:57.7084700 Output 354176 application/pdf Version of Record true 2020-04-17T00:00:00.0000000 Copyright © (2019) Massachusetts Medical Society. Reprinted with permission true
title	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
spellingShingle	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma John Wagstaff
title_short	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_full	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_fullStr	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_full_unstemmed	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
title_sort	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
author_id_str_mv	fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv	fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author	John Wagstaff
author2	Michele Maio Patrick Schöffski Matteo S. Carlino Céleste Lebbé Grant McArthur Paolo A. Ascierto Gregory A. Daniels Georgina V. Long Lars Bastholt Jasmine I. Rizzo Agnes Balogh Andriy Moshyk Massimo Guidoboni John Haanen Andrew Hill F. Stephen Hodi David Hogg Michael Smylie Pier F. Ferrucci Reinhard Dummer John Wagstaff Dirk Schadendorf C. Lance Cowey Christopher D. Lao Piotr Rutkowski Jean-Jacques Grob Rene Gonzalez Vanna Chiarion-Sileni James Larkin Ivan Márquez-Rodas Jedd D. Wolchok
format	Journal article
container_title	New England Journal of Medicine
container_volume	381
container_issue	16
container_start_page	1535
publishDate	2019
institution	Swansea University
issn	0028-4793 1533-4406
doi_str_mv	10.1056/nejmoa1910836
publisher	Massachusetts Medical Society
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	1
active_str	0
description	945 patients with inoperable stage III or stage IV melanoma were randomised to ipilimumab plus nivolumab (ipi/nivo)(314), nivolumab (nivo) (316) or ipilimumab (Ipilimumab) (315). The minimum follow up from randomisation of the last patient was 60 months. Objective responses were seen in 58% of Ipilimumab/nivo, 45% of nivo and 19% of Ipilimumab patients. Complete responses were seen in 22% (Ipilimumab/nivo), 19% (nivo) and 6% (Ipi) patients. Overall survival (OS) at five years was 52% (Ipilimumab/nivo), 44% (nivo) and 26% (Ipi). In patients with and without bras mutations the OS at five years was 60 & 48% (Ipilimumab/nivo), 46 & 43% (nivo) and 30 & 25% (Ipi) respectively. OS curves were flat beyond three years indicating that these treatments lead to sustained long term survival of these patients.
published_date	2019-10-17T04:05:04Z
_version_	1763753386141810688
score	11.035874

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Similar Items